Free Trial
NASDAQ:ELDN

Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis

Eledon Pharmaceuticals logo
$3.88 -0.02 (-0.51%)
Closing price 04:00 PM Eastern
Extended Trading
$3.88 +0.00 (+0.03%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Eledon Pharmaceuticals Stock (NASDAQ:ELDN)

Advanced

Key Stats

Today's Range
$3.84
$3.95
50-Day Range
$2.50
$4.14
52-Week Range
$1.35
$4.60
Volume
1.42 million shs
Average Volume
1.74 million shs
Market Capitalization
$299.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.67
Consensus Rating
Hold

Company Overview

Eledon Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

ELDN MarketRank™: 

Eledon Pharmaceuticals scored higher than 46% of companies evaluated by MarketBeat, and ranked 609th out of 864 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Eledon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on no strong buy ratings, 3 buy ratings, 1 hold rating, and 1 sell rating.

  • Upside Potential

    Eledon Pharmaceuticals has a consensus price target of $9.67, representing about 149.1% upside from its current price of $3.88.

  • Amount of Analyst Coverage

    Eledon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Eledon Pharmaceuticals' stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Eledon Pharmaceuticals is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Eledon Pharmaceuticals is -7.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Eledon Pharmaceuticals has a P/B Ratio of 2.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Eledon Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    11.16% of the float of Eledon Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Eledon Pharmaceuticals has a short interest ratio ("days to cover") of 3.62, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Eledon Pharmaceuticals has recently decreased by 3.32%, indicating that investor sentiment is improving.
  • Dividend Yield

    Eledon Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Eledon Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Eledon Pharmaceuticals has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Eledon Pharmaceuticals this week, compared to 2 articles on an average week.
  • Search Interest

    21 people have searched for ELDN on MarketBeat in the last 30 days. This is an increase of 2,000% compared to the previous 30 days.
  • MarketBeat Follows

    Only 3 people have added Eledon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -40% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    12.30% of the stock of Eledon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    56.77% of the stock of Eledon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Eledon Pharmaceuticals' insider trading history.
Receive ELDN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ELDN Stock News Headlines

The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it coming — but those who did walked away wealthy.Trump holds that same legal authority today. Advisors close to the administration believe he may use it.If he does, the transfer moves fast. The window to position yourself on the right side is already closing.tc pixel
See More Headlines

ELDN Stock Analysis - Frequently Asked Questions

Eledon Pharmaceuticals' stock was trading at $1.51 at the start of the year. Since then, ELDN shares have increased by 157.0% and is now trading at $3.88.

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) released its quarterly earnings data on Wednesday, May, 13th. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.11.

Eledon Pharmaceuticals (ELDN) raised $91 million in an initial public offering on Wednesday, September 17th 2014. The company issued 6,480,000 shares at a price of $13.00-$15.00 per share.

Eledon Pharmaceuticals' top institutional investors include SG Americas Securities LLC (0.84%), Bank of New York Mellon Corp (0.19%), Dimensional Fund Advisors LP (0.09%) and Mitchell & Pahl Private Wealth LLC (0.04%).
View institutional ownership trends
.

Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Eledon Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Today
5/13/2026
Last Earnings
5/13/2026
Next Earnings (Estimated)
5/13/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ELDN
CIK
1404281
Fax
N/A
Employees
10
Year Founded
2004

Price Target and Rating

High Price Target
$12.00
Low Price Target
$8.00
Potential Upside/Downside
+149.1%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.52)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$45.62 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-85.61%
Return on Assets
-31.93%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.40
Quick Ratio
7.40

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.35 per share
Price / Book
2.87

Miscellaneous

Outstanding Shares
77,190,000
Free Float
67,694,000
Market Cap
$299.50 million
Optionable
Optionable
Beta
0.94

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:ELDN) was last updated on 5/13/2026 by MarketBeat.com Staff.
From Our Partners